Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has shared an update.
Thiogenesis Therapeutics Corp has received scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use, supporting its submission of an Investigational Medicinal Product Dossier for a Phase 2a clinical trial targeting pediatric metabolic dysfunction-associated steatohepatitis (MASH). This trial will explore the safety and efficacy of TTI-0102, a prodrug of cysteamine, in children with MASH. Additionally, the company has been granted a European Union patent for its asymmetric disulfide prodrugs of cysteamine, enhancing its competitive position in the mitochondrial and metabolic disease sectors until 2038. These developments mark significant progress in Thiogenesis’s strategy to address serious pediatric conditions linked to mitochondrial dysfunction.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on developing next-generation thiol-based therapies for mitochondrial diseases and pediatric metabolic conditions. The company is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S.
Average Trading Volume: 30,131
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$34.73M
See more insights into TTI stock on TipRanks’ Stock Analysis page.